Galera Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Galera Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

83.1%

Buyback Yield

Total Shareholder Yield	83.1%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Jun 29

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Jun 15

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Mar 23

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 24

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Dec 24

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Nov 04

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Aug 05

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 17

Galera Therapeutics EPS beats by $0.08

Nov 10

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if GRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GRTX's dividend payments have been increasing.

Dividend Yield vs Market

Galera Therapeutics Dividend Yield vs Market

How does GRTX dividend yield compare to the market?
Segment	Dividend Yield
Company (GRTX)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.5%
Industry Average (Biotechs)	1.7%
Analyst forecast (GRTX) (up to 3 years)	0%

Notable Dividend: Unable to evaluate GRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate GRTX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GRTX has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/10 13:19
End of Day Share Price	2025/02/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galera Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tazeen Ahmad	BofA Global Research
null null	BTIG
Yigal Nochomovitz	Citigroup Inc

Galera Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Galera Therapeutics Announces Board Changes

Galera Therapeutics Announces Board Appointments

Galera Therapeutics, Inc., Annual General Meeting, Feb 24, 2025

Galera Therapeutics, Inc. announced delayed 10-Q filing

Galera Therapeutics, Inc. announced delayed 10-Q filing

The Nasdaq Stock Market LLC to Delist Common Stock of Galera Therapeutics

Galera Therapeutics, Inc. Eliminates Robert A. Beardsley as Chief Operating Officer

Galera Therapeutics, Inc.(OTCPK:GRTX) dropped from S&P TMI Index

Nasdaq Hearings Panel Determines to Delist Galera Therapeutics' Shares from Nasdaq Due to the Failure to Meet Nasdaq’s Continued Listing Standards

New major risk - Financial position

Galera Therapeutics Receives Non-Compliance Letters from the Listing Qualifications Staff of Nasdaq

New major risk - Market cap size

New major risk - Revenue and earnings growth

Price target increased by 25% to US$0.50

Insufficient new directors

Galera Therapeutics Receives Notice from Nasdaq Regarding Listing Rule 5450(B)(2)(C)

Galera Therapeutics Receives Two Non-Compliance Notices from Nasdaq

New minor risk - Share price stability

Galera Therapeutics, Inc. Approves Reduction in the Company's Current Workforce by 22 Employees, or Approximately 70% of the Company's Headcount

Consensus revenue estimates increase by 17%

New minor risk - Market cap size

Galera Therapeutics, Inc. Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

Insufficient new directors

Consensus revenue estimates increase by 100%

Price target decreased by 11% to US$10.00

CEO, President & Director recently bought US$168k worth of stock

Price target increased by 11% to US$12.50

Galera Therapeutics, Inc. Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

Galera Therapeutics Receives Non-Compliance Notice from Nasdaq

Price target decreased to US$11.25

Price target increased to US$15.00

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics, Inc Appoints Eugene P. Kennedy as Chief Medical Officer

Galera Therapeutics appoints chief medical officer

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Results from Phase 1 Stage of Greco-1 Trial of Rucosopasem with SBRT for Nsclc

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Galera Therapeutics Receives Non-Compliance Letter from Nasdaq

Galera Therapeutics, Inc. Announces Oral Presentation At 2022 American Society of Clinical Oncology Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Galera Announces Plan to Submit Avasopasem NDA by Year End

Galera Therapeutics, Inc. Announces Topline Results from Phase 2A Aesop Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

Galera to Present at 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$12.25

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Independent Director recently bought US$55k worth of stock

Galera Therapeutics, Inc. Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Price target decreased to US$11.50

Chief Medical Officer exercised options and sold US$288k worth of stock

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000E Index

Independent Director recently bought US$91k worth of stock

Galera Therapeutics, Inc. Ceases Enrolling Subjects in its Phase 2 Pilot Trial of Avasopasem in Hospitalized Patients

Independent Director recently bought US$173k worth of stock

Consensus forecasts updated

Galera Therapeutics, Inc. Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

Price target increased to US$20.75

CEO, President & Director exercised options to buy US$1.8m worth of stock.

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

New 90-day high: US$12.39

Chief Accounting Officer exercised options and sold US$179k worth of stock

Galera Therapeutics EPS beats by $0.08

New 90-day high: US$12.81

New 90-day high: US$9.81

New 90-day low - US$6.96

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000 Value Index

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell Microcap Value Index

Stability and Growth of Payments